<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647982</url>
  </required_header>
  <id_info>
    <org_study_id>MT01-KR17PAH110</org_study_id>
    <nct_id>NCT03647982</nct_id>
  </id_info>
  <brief_title>Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers</brief_title>
  <official_title>Open-Label, Active Controlled, Single-Center, Phase 1 Study to Determine the Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the anhidrotic area and safety of MEDITOXIN
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">November 20, 2018</completion_date>
  <primary_completion_date type="Actual">October 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anhidrotic area</measure>
    <time_frame>week 4</time_frame>
    <description>After the ninhydrin sweat test, measure the area of the unstained area</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Anhidrotic Area</condition>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 3U(25U/1ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 10U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 3U(50U/1ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 3U(12.5U/1ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meditoxin</intervention_name>
    <description>injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses</description>
    <arm_group_label>botulinum toxin 10U</arm_group_label>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_label>botulinum toxin 3U(12.5U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 3U(25U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 3U(50U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>injection of Botox into the intradermal of each contralateral upper back in equal doses</description>
    <arm_group_label>botulinum toxin 10U</arm_group_label>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_label>botulinum toxin 3U(12.5U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 3U(25U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 3U(50U/1ml)</arm_group_label>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male adults aged between 20 and 45 years

        Exclusion Criteria:

          -  Subjects not appropriate for participating in this study according to the
             investigator's opinion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University St. Paul Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

